Longitudinal outcomes of patients enrolled in a phase Ib clinical trial of the adipose‐derived stromal cells‐stromal vascular fraction in idiopathic pulmonary fibrosis

Abstract

Significant functional decline occurred at 24 months after first administration. The median survival and time to progression are in line with the published epidemiologic data. Further clinical trials complemented by mechanistic studies are sorely needed to delineate the role of ADSCs in IPF pathogenesis and treatment.